Ultimately, the primary reasons why people use CBD is because it tends to have calming, relaxing, pain-reducing effects. It has been used to alleviate joint pain and nerve pain, reduce anxiety and stress, treat insomnia, improve migraines, and address nausea.
Wendy Rose Gould is a lifestyle reporter with over a decade of experience covering health and wellness topics.
She adds, “[Another difference is that] CBD is derived from hemp and has been classified as a legal substance. Hemp has <0.3% THC. Conversely, cannabis plants such as marijuana are grown to have much higher levels of THC and are still illegal according to the FDA, although individual states vary as to their use.”
Are There Any Benefits Associated With Using CBD?
The most comment side effects of CBD include drowsiness, gastrointestinal issues, dry mouth, reduced appetite, nausea, and interaction with other medications. Those are outlined in detail below.
“Since discovering the endocannabinoid system (ECS) in the body in the 1990s, CBD has been researched more extensively. The ECS is a central regulatory system restoring normal balance and homeostasis in a range of human physiologic systems throughout the body and brain and has cannabinoid receptors and chemicals in its function,” explains Dr. Matharu-Daley.
Generally speaking, CBD is considered a safe substance when applied topically or taken orally. There are, however, some potential side effects to keep in mind when using this substance, the majority of which are mild.
There are several reasons why someone might want to use CBD. The substance can be found in a multitude of products ranging from pain-relieving creams to edible tinctures to skincare. Research is still underway, but over the last few decades scientists have become more aware of how CBD might ibeneficial when applied either topically or ingested.
CBD’s exact mechanism of action is unclear. Unlike THC, CBD has a relatively low affinity for cannabinoid receptors in the brain. These are the molecules to which THC binds to elicit its psychoactive effects.
Common symptoms include:
CBD oil may benefit those with drug addiction, suggests a 2015 review of studies published in Substance Abuse.
In an analysis of 14 published studies (nine involving animals and five involving humans), scientists with the University of Montreal concluded that CBD showed promise in treating people with opioid, cocaine, or psychostimulant addiction.
Among the few human trials evaluating CBD’s anxiolytic effects was one published in the Brazilian Journal of Psychiatry in 2019. For this study, 57 men were given either CBD oil or a placebo before a public-speaking event. Anxiety was evaluated using physiological measures (such as blood pressure, heart rate, etc.) and a relatively reliable test for mood states known as the Visual Analog Mood Scale (VAMS).
Dalton WS, Martz R, Lemberger L, et al. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 1976;19(3):300-9. View abstract.
Harvey, D. J., Samara, E., and Mechoulam, R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem.Behav. 1991;40(3):523-532. View abstract.
Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 2009;23(8):979-83. View abstract.
Possibly Effective for
Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132(1):56-61. View abstract.
Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-92. View abstract.
Resstel LB, Tavares RF, Lisboa SF, et al. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioral and cardiovascular responses to acute stress in rats. Br J Pharmacol 2009;156(1):181-8. View abstract.
Leighty EG, Fentiman AF Jr, Foltz RL. Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 1976;14(1):13-28. View abstract.